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Abstract Alzheimer’s disease (AD) is a prevalent, long-term
progressive degenerative disorder with great social impact. It
is currently thought that, in addition to neurodegeneration,
vascular changes also play a role in the pathophysiology of
the disease. Visual symptoms are frequent and are an early
clinical manifestation; a number of psychophysiologic chang-
es occur in visual function, including visual field defects, ab-
normal contrast sensitivity, abnormalities in color vision,
depth perception deficits, and motion detection abnormalities.
These visual changes were initially believed to be solely due
to neurodegeneration in the posterior visual pathway.
However, evidence from pathology studies in both animal
models of AD and humans has demonstrated that neurodegen-
eration also takes place in the anterior visual pathway, with
involvement of the retinal ganglion cells’ (RGCs) dendrites,
somata, and axons in the optic nerve. These studies addition-
ally showed that patients with AD have changes in retinal and
choroidal microvasculature. Pathology findings have been
corroborated in in-vivo assessment of the retina and optic
nerve head (ONH), as well as the retinal and choroidal vascu-
lature. Optical coherence tomography (OCT) in particular has
shown great utility in the assessment of these changes, and it
may become a useful tool for early detection and monitoring
disease progression in AD. The authors make a review of the
current understanding of retinal and choroidal pathological
changes in patients with AD, with particular focus on in-
vivo evidence of retinal and choroidal neurodegenerative
and microvascular changes using OCT technology.
Keywords Alzheimer’s disease . Optical coherence
tomography (OCT) . Retina . Choroid
Introduction—Alzheimer’s disease (AD)
Alzheimer’s disease (AD) is a long-term progressive neurode-
generative disorder affecting the central nervous system (CNS).
It is the most common cause of dementia, affecting about 6 % of
the population aged over 65, and the clinical incidence doubles
every 5 years after 65 years of age [1, 2]. Over 26 million people
are estimated to suffer from AD, and this number is expected to
quadruple by 2050 [3]. It is therefore a disease with a great social
impact, leading to considerable impairment in quality of life for
both patients, family members, and healthcare workers.
Its pathophysiology remains incompletely understood. The
earliest AD pathological change in the CNS is the accumula-
tion of amyloid β (Aβ), derived from abnormal processing of
amyloid precursor protein (APP). This process begins approx-
imately 10 years before the onset of the clinical syndrome of
dementia, which is characterized by a constellation of symp-
toms and signs manifested by difficulties in memory, distur-
bances in language, and psychological and psychiatric chang-
es including behavioral disturbances, executive dysfunction,
and impairment in activities of daily living [1, 4]. Clinical
progression shows great variability among patients.
Mild cognitive impairment (MCI) is an intermediate state
of cognitive function between normal aging and early demen-
tia, in which patients may have one ormore cognitive domains
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affected, without impairment in activities of daily living. It is
considered a risk factor for Alzheimer’s disease, with variable
progression to AD [5].
Visual changes in AD patients
Visual symptoms are frequently among the earliest symptoms
in patients with Alzheimer’s disease, and visual function is
affected in most patients with AD, contributing to further im-
pairment in quality of life.
There are a number of changes in visual function in AD
patients including visual field defects, predominantly in the
inferior hemifield, abnormal contrast sensitivity, and abnor-
malities in color vision, depth perception, and visual sensitiv-
ity to motion [6]. Other psychophysiological changes such as
visual acuity and pupillary changes have been studied in pa-
tients with AD, with conflicting findings.
In addition, more complex visual symptoms may arise ear-
ly in the history of AD, including visual memory deficits and
visual hallucinations [7, 8].
However, the results of visual tests are dependent on the
patient’s understanding, memorization, vigilance, and compli-
ance to the rules and the test instructions, which depends on
the cognitive status of each patient. The ability to cooperate in
some visual tests can be affected additionally by ocular motor
abnormalities that may be present in patients with AD, such as
slower saccadic movements and changes in smooth pursuit
movement [9, 10]. Some of this data may thus be the result
of poor compliance related to the cognitive status rather than
the result dysfunction of the visual pathways [11].
Neuropathology of the visual system in AD
The two most important neuropathological features of AD are
cerebral Aβ-amyloid neuritic plaques in neocortical terminal
fields, and neurofibrillary tangles (NFTs) containing phos-
phorylated tau protein [12–14] initially in medial temporal-
lobe structures and later in many forebrain and midbrain areas.
Microvascular amyloid deposition (amyloid angiopathy),
granulovacuolar degeneration, loss of neurons and white mat-
ter, synapse loss, gliosis, inflammation, and oxidative damage
are other pathological changes present in AD [12–15].
AD pathological changes in the posterior visual pathway
Neurodegenerative changes have been demonstrated in most
visual systems in AD. In fact, degenerative changes in the visual
pathways occur early in the disease process of Alzheimer’s, even
before the onset of clinical symptoms of dementia [15, 16].
The visual cortex is relatively spared, and visual associa-
tion areas (V2, V3) are more affected than primary visual
cortex (area V1). In the primary visual cortex, the density of
neuritic plaques and NFTs has been shown to be significantly
greater in the cuneal gyrus compared to the lingual gyrus. This
may account in part for the predominantly inferior VFDs in
patients with AD [9].
Degeneration of lateral geniculate nucleus (LGN) has been
documented in patients with AD [17]. Couser and Bernstein
(2014) observed the presence of AD-related markers in the
lateral geniculate nucleus (LGN), proposing that AD-related
changes take place in this structure very early in the disease
process [18].
Neurodegenerative changes also occur in the suprachias-
matic nucleus (SCN) [19]. This hypothalamic region is in-
volved in sleep-wake circadian rhythm, receiving direct input
from RGCs via the retino-hypothalamic tract. Degeneration of
the SCN may account for the sleep disturbances found in
patients with AD. Regarding sleep disturbances in AD, it is
of note that recent studies documented impairment of
melanopsin RGCs (m-RGCs) in the retina of patients with
AD. m-RGCs are a population of RGCs (1–2 % of total
RGC population) involved in non-image-forming visual func-
tions, including photoentrainment of circadian rhythms [20].
In this study, m-RGC density was significantly decreased in
the AD group compared with controls, and remaining m-
RGCs presented impaired function, altered morphology, and
amyloid deposits in and around these cells. These changes
occurred in m-RGCs even with normal RGC counts, suggest-
ing these cells may be specifically affected in AD. Further
studies are necessary to understand whether trans-synaptic
retrograde degeneration due to SCN pathology might or might
not play an additional role in m-RGC loss in AD.
Oculomotor brain nuclei, namely the superior colliculus
(SC), are also affected by AD-related neurodegenerative pro-
cesses [21]. This may account, at least in part, for the abnor-
malities in eye movements previously described. There ap-
pears to be also amyloid plaque deposition and NFTs in
pulvinar nuclei of patients with AD, which may explain im-
paired visual attention in AD patients [22].
Pathological changes in the retina and optic nerve
Visual defects in AD patients were initially thought to be
solely due to parietal and primary visual cortex pathology.
However, increasing evidence has demonstrated that anterior
visual pathway degeneration also plays a role. Hinton et al.
first provided histopathological evidence of optic neuropathy
and degeneration of retinal ganglion cells (RGC) in patients
with AD, with a reduced number of RGCs and reduced retinal
nerve fibre layer (RNFL) thickness [23]. Later, post-mortem
studies showed that degeneration of the ganglion cell layer
(GCL) occurs preferentially in superior and inferior quadrants,
as well as in the central retina, in particular the temporal foveal
region [24, 25]. Initially, a preferential loss of magnocellular
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RGC axons in the optic nerve was described [26], but other
evidence suggests parvocellular RGC axon loss also takes
place in AD [17]. Since then, pathology studies of AD pa-
tient’s eyes have documented increased APP immunoreactiv-
ity, Aβ and pTau deposits in the internal retinal layers (GCL,
RNFL), retinal pigmentary epithelium, and retinal vasculature
[27, 28], as well as reduction of choroidal thickness [29].
Animal models of AD have provided further insight regard-
ing retinal changes in Alzheimer’s disease. A study using
mouse models of AD demonstrated that formation of neuritic
plaques in the retina and choroidal vasculature occurs prior to
their manifestation in the brain [27], and amyloid deposits were
found in RNFL, RGCs, internal retinal layers, and even in the
photoreceptor outer segments. Interestingly, this study also an-
alyzed post-mortem human retinae of patients with AD, and
observed a relation between severity of dementia and retinal
amyloid plaque burden.
Evidence has emerged that degeneration of RGC dendritic
processes in the internal plexiform layer (IPL) may take place
before RGC loss, suggesting synaptic dysfunction may be an
early change in the neurodegenerative process [30]. In addition,
activated glial cells, hypertrophy of retinal pigmented epithelial
cells, and choroidal inflammation have also been observed in
the eyes of mouse models of Alzheimer’s disease [3].
These neuropathological findings have raised the possibility
that the changes in the retinae of patients with ADmay be due to
both direct retinal pathology and trans-synaptic retrograde degen-
eration. Trans-synaptic retrograde degeneration (TRD) of neu-
rons is a process occurring after central nervous system lesions,
in which degeneration of the axon proceeds towards the cell
body, as opposed to anterograde (Wallerian) degeneration. This
creates a hostile, neurotoxic environment that leads to secondary
degeneration of neighboring neurons. TRDhas been demonstrat-
ed in a number of neurological pathways; interest in TRD in the
visual pathway has arisen since Van Buren et al. (1963) first
observed atrophy of the right LGN and retinal ganglion cells
(RGCs) following right occipital lobectomy in an adolescent
monkey [31]. Later, pathology studies in humans with occipital
lesions also revealed changes in LGN [32]. Clinical evidence
further supported this hypothesis. Fletcher et al. (1988) described
optic disc pallor and band atrophy in individuals with congenital
occipital lesions. Initially it was believed that TRD in the visual
pathway occurred only in individuals with congenital (prenatal)
occipital lobe lesions [33], although recent studies have also
provided evidence that TRD of RGC can also occur in patients
with acquired occipital lobe lesions [34–36].
Imaging of retina, optic nerve, and choroid in AD
In-vivo morphological studies have provided further evidence
of both direct involvement of the retina and optic nerve head,
and TRD processes in patients with AD, as well as choroidal
changes.
Initial in-vivo non-invasive studies of optical neuropathy in
patients with Alzheimer’s disease using fundus photographs
showed retinal nerve fibre layer (RNFL) abnormalities, as
well as macular changes and ONH abnormalities (increased
cup-to-disc ratio and decreased neurorretinal rim) [37–39].
Increased cup-to-disc ratio has been reported to correlate with
RNFL thinning in AD [40–42], and cup-to-disc ratio may be
correlated with duration of disease [37]. This method, howev-
er, has certain disadvantages, as it is manual and highly sub-
jective to each individual observer [41].
Later noninvasive studies of RNFL and ONH using scan-
ning laser ophthalmoscopy (SLO) [42], and time-domain
OCT (TD-OCT) studies confirmed the reduction in
peripapillary RNFL thickness [40, 43–47]. In addition, in-
vivo studies have shown reduced macular thickness and vol-
ume in patients with AD [44, 48–54].
Pathological changes in Alzheimer’s disease not only in-
volve neurodegeneration, but also the vasculature. The notion
of AD as a disease of the neurovascular unit emerged from the
findings of cerebral amyloid angiopathy, frequent focal chang-
es in brain microcirculation, and especially because these vas-
cular changes in AD are intimately associated with the typical
neuronal degenerative changes [55]. Recent evidence has
raised the possibility that the retinal microvasculature is affect-
ed in AD. Laser Doppler studies have shown altered retinal
blood flow in patients with AD, although no correlation was
found between RNFL thickness and retinal blood flow [45].
Two recent studies using retinal photography found retinal
vascular abnormalities, including vascular attenuation, re-
duced branching pattern, and altered venular tortuosity [54,
56, 57]. According to the authors, these retinal vascular chang-
es in AD may be correlated with the neocortical amyloid
plaque burden [58] or may mirror the cerebral microvascular
pathology [54].
The choroid also appears to be affected in AD. Atrophy of
the choriocapillaris has been shown to occur with normal ag-
ing, and age-dependent amyloid accumulation in the choroid
vasculature has been demonstrated in mice and also in trans-
genic mouse models of AD [59].
Optical coherence tomography—a potential new
biomarker for detection of AD
Early optical coherence tomography studies have shown
peripapillary RNFL thinning in AD patients, although dis-
crepancy has been found concerning which quadrants were
most affected. More recent OCT studies have reported also
macular changes in the ganglion cell complex (GCC), com-
prising the ganglion cell layer (GCL) and inner plexiform
layer (IPL). Also, choroidal thickness [60] has been shown
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to be reduced in patients with AD, as measured by EDI-OCT
Spectralis Heidelberg [61–63].
The evaluation of visual changes in AD patients has been
difficult, due to difficulties in patient collaboration, and limi-
tations in diagnostic exams to overcome these difficulties.
These factors have long interfered with the interpretation of
findings in these patients.
Nevertheless, results from the studies of retinal and choroi-
dal changes in AD patients have raised the possibility that
OCT may be a non-invasive clinical biomarker for the early
detection of AD. Retinal changes may be an early event in the
course of AD, and retinal OCT may provide insights for
assessing neurodegeneration in the brain [50].
OCT is a reliable non-invasive, trans-pupillary technique
that provides high-resolution cross-sectional images of RNFL
and macular volume, allowing visualization of axons of the
central nervous system (CNS) and evaluation of RNFL thick-
ness [39, 41]. Peripapillary RNFL thickness (RNFLT) is
Fig. 1 Reduced RNFL thickness in Alzheimer’s Disease, as measured by SD-OCT (Spectralis Heidelberg). In this case, diffuse RNFL thinning is
documented, in particular due to thinning in the temporal superior and temporal inferior sectors
Fig. 2 Automatic segmentation
of retinal layers in macular region
as measured by SD-OCT
(Spectralis Heidelberg)
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believed to reflect axonal loss, whereas macular volume re-
flects neuronal loss of RGC, since the neuronal bodies and
dendrites are located in the ganglion cell/internal plexiform
layer (GC-IPL), mostly in the macula lutea [50].
TD-OCT has been the most widely employed ocular imag-
ing technique for assessment of optic nerve degeneration in
AD [43–47], as well as for evaluating macular thinning in
these patients [44].
Spectral-domain OCT (SD-OCT), a Fourier domain OCT
technique, provided dramatically increased scanning speed
and higher axial resolution when compared to TD-OCT tech-
nology, allowing the study of RGC and analysis of the GC-
IPL layers [41, 49]. SD-OCT has been validated as a reliable
technique for detecting subclinical RNFL and retinal atrophy
in AD [64–66]. A number of studies using this technology
have corroborated peripapillary RNFL thinning findings from
TD-OCT studies. Figure 1 shows these changes in pRNFL
thickness. In addition, one study using SD-OCT showed a
diffuse reduction of the RNFL and GCL combined in AD
[49], although the authors were not able to determinate which
layer was most affected by AD. Later studies have demon-
strated IPL thinning in AD patients [41, 50, 52, 56, 57]. This
reduction of ganglion cell complex thickness (GC-IPL and
RNFL layers) in AD occurs to a larger extent than that
accounted for age-related GC-IPL loss alone (about 0.3 μm/
year) [54]. Macular GC-IPL thinning may be a more sensitive
marker of earlier neurodegeneration in MCI and AD than
evaluation of the retinal fibre layer. These findings are in
agreement with the pathological findings of direct retinal in-
volvement in dementia. Figure 2 illustrates the GC-IPL thin-
ning as measured by SD-OCT.
Evidence fromOCTstudies also supports a role for TRD in
disorders of the posterior visual pathway [34, 35, 67, 68] with
visual field defects in these disorders correlating best with
macular GCL thickness than with RNFL thickness [67, 68].
Likewise, OCT findings in AD suggest the contribution of
TRD in the pathophysiology of visual changes. In addition
to previous OCT studies showing reduced peripapillary
RNFL thickness, a recent SD-OCT study found that reduced
grey matter volumes of occipital and temporal lobes was in-
dependently associated with thinning of the GC-IPL and
peripapillary RNFL in individuals without dementia [69].
Since those cortical regions are an early site of deposition of
senile plaques and NFTs, the findings by Y.-T. Ong and co-
workers raises the possibility that GC-IPL thinning may re-
flect neurodegenerative changes in the brain, even before the
clinical onset of dementia.
Some questions remain to be answered before consid-
ering OCT a useful clinical biomarker for early detection
of dementia and assessment of disease progression in AD.
As stated earlier, peripapillary RNFL thinning has been
demonstrated in a number of studies. However, differences
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most affected. While some studies report preferential su-
perior quadrant RNFL thinning in AD, which would ex-
plain the predominantly inferior visual field defects previ-
ously described in AD [40, 45, 47, 54, 70–72], other
authors have reported different findings; these results are
presented in Table 1. A meta-analysis of TD-OCT studies
in AD demonstrated that peripapillary RNFL thinning oc-
curred in all retinal quadrants [73]. However, more recent
SD-OCT studies have reported different findings, with
most SD-OCT studies suggesting selective superior
RNFL thinning [39, 54, 70]. Two more recent meta-anal-
yses, which used both TD-OCT and SD-OCT studies,
aimed to determine the diagnostic utility of OCT measure-
ments of RNFL thickness in AD [74, 75]. While
confirming significant peripapillary RNFL thinning in
AD, these meta-analyses reached different conclusions re-
garding which quadrants are most affected. Whether or not
a correlation exists between retinal changes and severity of
dementia also remains a controversial issue. While most
OCT studies did not show correlation between Minimal
Mental State Examination (MMSE) and peripapillary
RNFL thinning (Table 2), one TD-OCT study reported
correlation between MMSE scores and macular volume
[44], and more recent studies using SD-OCT have indeed
reported a significant correlation between MMSE scores
and RNFL thickness [50, 66, 72, 76, 77]. Studies compar-
ing changes in RNFLT in MCI and AD (Table 2) have
also yielded conflicting results, although the majority re-
ported no statistically significant differences between MCI
and AD patient groups [46, 47, 54, 77]. The meta-
analyses by K.L. Thomson et al. and G. Coppola et al.
[74, 75] also tried to determine the utility of OCT as a
tool for evaluating disease progression, and prognostic sig-
nificance of GC-IPL and RNFL thickness in MCI and
AD. Both meta-analyses concluded that OCT can be used
to detect early abnormalities in MCI, but their conclusions
regarding which retinal quadrants are affected in MCI
were conflicting—one concluded that MCI patients have
selective superior quadrant RNFL thinning [74], while the
other concluded that all quadrants but the superior one
were affected [75]. In addition, they failed to determine
a correlation between RNFL and clinical severity of de-
mentia [74].
Spectral-domain OCT (SD-OCT) using enhanced depth
imaging modality (EDI) is a technology that allows visualiza-
tion of the deeper structures of the eye such as the choroid.
Choroidal thickness (CT) varies topographically within the
posterior pole, being thickest under the fovea and thinnest in
the nasal area. EDI-OCT has been validated as a reproducible
modality for subfoveal CT measurements [60]. In addition,
EDI-OCT findings have confirmed that CT significantly de-
creases with older age.
Choroidal thickness (CT) has been shown to be re-
duced in all regions in patients with AD, as measured
by EDI-OCT Spectralis Heidelberg [61]. Figure 3 de-
picts these changes in choroidal thickness. These find-
ings have been corroborated by further studies [62, 63].
One study also included patients with MCI, and ob-
served reduced CT in this group, although no statistical-
ly significant differences between the MCI and AD pa-
tient groups were found [63]. Although CT is reduced,
it remains to be elucidated whether or not choroidal
thinning is correlated with MMSE scores, as authors
report conflicting results. The results of these studies
are shown in Table 3.
Swept source-OCT (SS-OCT) is another Fourier do-
main OCT technology. It has also an improved signal-
to-noise ratio as compared to TD-OCT, providing higher
image resolution. SS-OCT additionally offers some ad-
vantages over SD-OCT, including higher detection effi-
ciency, increased sensitivity with image depth, reduced
fringe washout and longer imaging range, higher pene-
tration into the ONH and choroid, and lowered sensitiv-
ity to ocular opacities [41].
Ultrahigh-speed OCT based on swept laser technology en-
ables rapid 3D imaging of the retina and Doppler OCT exam-
ination of ocular circulation with a non-invasive ocular angi-
ography by optical coherence tomography. This can be a pow-
erful methodology for measuring total retinal blood flow,
which might be beneficial for assessing pathologic changes
in diseases with impaired circulation of retina and choroid
such as AD [78].
Fig. 3 Choroidal thickness (CT) as measured by EDI-OCT (Spectralis Heidelberg)
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Conclusions
Patients with signs and symptoms of dementia undergo neu-
ropsychological evaluation, and several clinical tools have
been validated for that purpose, including the Clinical
Dementia Rating (CDR) and Alzheimer ’s Disease
Assessment Scale (ADAS). Diagnostic criteria can be used
for clinical diagnosis of Alzheimer’s disease, namely the
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) criteria
[68] and the Diagnostic and Statistical Manual of Mental
Disorders (DSM-V) criteria. However, to date, the definitive
diagnosis of AD can still only be made on pathologic exam-
ination. However, a number of diagnostic exams have been
considered to be supportive of the clinical diagnosis.
Neuroimaging technologies, namely computerized tomogra-
phy (CT) scanning or magnetic resonance imaging (MRI)
have shown medial temporal lobe atrophy. Reduced brain ac-
tivity has been detected by changes in glucose metabolism in
positron emission tomography (FDG-PET). Biochemical ce-
rebrospinal fluid (CSF) markers have been suggested as po-
tential biomarkers for early detection of Alzheimer’s disease
(decreased levels of CSF Aβ42 protein and increased CSF
levels of tau and phosphorylated tau proteins) [79, 80].
Cicero (106–43 BC) stated Bthe face is a picture of mind as
the eyes are its interpreter^; Matthew reveals in the Bible Bthe
eye is the lamp of the body ,^ and it is attributed to Shakespeare
the quote Bthe eyes are the window to the soul^.
Optical coherence tomography findings in many neurode-
generative diseases have revived this notion of the eye as the
Bwindow to the brain^. Anatomically and embryologically,
the retina is known as an extension of the central nervous
system; the fibers of retinal ganglion cell axons forming the
optic nerve are the axons of the CNS and the retinal and
cerebral vasculature share similar anatomic, physiological,
and embryological characteristics.
OCT studies have provided useful information regarding
retinal and choroidal changes in the eyes of patients with
AD, as OCT findings are consistent with the findings from
pathology studies of both human and animal models of AD. In
addition, retinal changes in microvasculature may reflect mi-
crovascular disease in the brain.
These findings may render OCT a useful clinical tool for
diagnostic and prognostic evaluation of MCI and AD patients.
Newer, more sensitive imaging modalities for measurements of
retinal layers and choroidal thickness will allow further under-
standing of the earliest changes in the retina of these patients. It
is likely that macular inner retinal layers (GC-IPL and macular
RNFL) neurodegenerative changes are the earliest events,
followed by peripapillary RNFL thinning, but vascular changes
both in choroid and in retina may also play a role in the initi-
ation of the neurodegenerative processes. Further OCT studies
are thus needed to determine the progression of these
neurovascular degenerative changes in MCI and AD.
Literature research
We searched the PubMed and Google Scholar databases to
identify articles published up to 27th March 2016, using the
following key terms: BAlzheimer’s disease^, Bdementia^,
Boptical coherence tomography ,^ Bvisual function
abnormalities^. In addition, we manually searched the refer-
ence lists of most primary articles and reviewed articles.
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